Abstract: Harmful fungi in nature not only cause diseases in plants, but also fungal infection and poisoning when people and animals eat food derived from crops contaminated with them. Unfortunately, such fungi are becoming increasingly more resistant to traditional synthetic antifungal drugs, which can make prevention and control work increasingly more difficult to achieve. This means they are potentially very harmful to human health and lifestyle. Antifungal peptides are natural substances produced by organisms to defend themselves against harmful fungi. As a result, they have become an important research object to help deal with harmful fungi and overcome their drug resistance. Moreover, they are expected to be developed into new therapeutic drugs against drug-resistant fungi in clinical application. This review focuses on antifungal peptides that have been isolated from bacteria, fungi, and other microorganisms to date. Their antifungal activity and factors affecting it are outlined in terms of their antibacterial spectra and effects. The toxic effects of the antifungal peptides and their common solutions are mentioned. The mechanisms of action of the antifungal peptides are described according to their action pathways. The work provides a useful reference for further clinical research and the development of safe antifungal drugs that have high efficiencies and broad application spectra.

Keywords: antifungal peptide; antibacterial activity; antibacterial stability; cytotoxicity; antifungal mechanism

1. Introduction

Fungi are eukaryotic microorganisms that exist widely in nature and include molds, yeasts, and so on. Many of them, e.g., Fusarium graminearum, Aspergillus ochraceus, A. flavus, are a great threat to the normal growth of crops, foodstuffs, and feed safety. When mycotoxins are ingested to a certain level by humans and livestock, they cause serious adverse reactions, such as, fungal infection, hepatorenal toxicity, carcinogenesis, and teratogenesis [1].

Every year, huge economic losses are incurred in the process of growing, storing, and transporting crops due to mildew. Such losses have a great impact on our food production industry and our lives. Unfortunately, most of the antifungal drugs that can be used in the treatment of fungal diseases are polyenes, triazoles, echinocandins, and some other auxiliary drugs (e.g., 5-fluorocytosine), the application of which can be toxic to patients to different degrees. Worse still, more and more drug-resistant strains are emerging [2,5], and the drug resistance of some fungi is also rising year-by-year [4,5]. This suggests there is an urgent need to develop new antifungal drugs [6].

Antimicrobial peptides are small molecules produced by organisms that play an important role in the innate immunity of the organism [7] (the name was first formally proposed by the Swedish scientist G. Boman in 1981 [8]). These antimicrobial peptides
are not only active against pathogenic microorganisms directly but also play a role in regulating the autoimmune system of the host. Thus, they have wide application prospects in the prevention and treatment of animal- and plant-related diseases, the development of new drugs, and the field of biological detoxification [9].

Antifungal peptides are antimicrobial peptides with antifungal activity. Scientists isolated antifungal substances from Bacillus subtilis as long ago as 1948 [10]. Since then, some studies on the mode of action and biosynthesis of antifungal antibiotics began to appear [11,12]. Boman et al. also found substances with antifungal effects in their continued studies of antimicrobial peptides that they had previously discovered [13]. To date, there are about 2700 kinds of antimicrobial peptides in the Antimicrobial Peptide Database, but only 1000 or so have antifungal activity. At present, many antifungal peptides are found and defined as part of studies generally aimed at antimicrobial peptides. However, targeted research on antifungal peptides is developing rapidly, and there are many kinds of antifungal peptides that have been isolated and purified from microorganisms.

In this review, the antifungal peptides available from microbial sources are summarized and discussed according to different classification methods. The aim is to produce a reference work that will be helpful for those conducting further research in this field in the future.

2. Microorganisms Producing Antifungal Peptides

There are three kinds of microorganism that produce antifungal peptides: bacteria, fungi, and actinomycetes. Of these, bacteria form the largest group of sources, of which Bacillus subtilis, B. amyloliquefaciens, B. cereus, and so on are widely used in research on biological control.

Li et al. extracted and analyzed an antifungal substance from a strain of B. amyloliquefaciens sybc H47 and found that it had a significant effect on a variety of pathogenic fungi, e.g., Aspergillus niger, Fusarium oxysporum, Penicillium citrinum, and Candida albicans [14]. Other bacterial species can also produce antifungal peptides, but the number of papers on them is far less than those related to Bacillus species (at present).

Many fungi have been found to synthesize antifungal peptides. For example, Aspergillus can synthesize echinocandins that are resistant to invasive fungal infections [15].

With the rapid development of antifungal peptide research, people are not satisfied with the discovery of new antifungal active substances only from terrestrial microorganisms. As a result, researchers are beginning to focus on ocean sources. For example, the excellent antifungal activity of marine actinomycetes has attracted more and more attention from researchers in recent years [16]. Streptomyces species have been widely studied and found to have many other functions in addition to antifungal activity. For example, they also have antibacterial, antiviral, and antiparasitic properties, etc., which makes them very valuable in the development of new antibiotics [17].

Table 1 presents a summary of the antifungal microorganisms of different species found to date as well as the species of fungi they act upon. It can be seen that most of the antifungal peptides have broad-spectrum antifungal effects (i.e., they can act on a variety of pathogenic fungi of the same or different species of relevance to plants and animals). Researchers are also working to expand the antibacterial spectra of antifungal substances that act upon single antifungal species by changing the structures of the compounds involved. For example, naturally occurring echinocandins and their semisynthetic derivatives are limited by their narrow antibacterial spectra. For instance, the activity spectrum of anidulafungin only includes Candida and Aspergillus infections—it has no activity against Cryptococcus spp., Fusarium spp., or Trichosporon spp. [18]. On the basis of the existing structure–activity relationship, researchers subsequently synthesized a variety of cyclohexalipopeptide compounds. The activity test results show that some of these synthesized compounds not only have stronger anti-Candida albicans activity than caspofungin but also feature in vitro inhibitory activity against Cryptococcus neoformans, Aspergillus fumigatus, and Trichoderma rubrum [19].
Structural modification may also help improve the solubility and stability of such drugs in addition to expanding their antibacterial spectra [20]. Moreover (as can be seen from Table 1), the antifungal targets of many antifungal peptides from different sources overlap. This means that combinations of drugs can be used that will help reduce drug resistance. The antibacterial effects of many antifungal peptides are very significant [15], and therefore their minimum inhibitory concentrations (MICs) are correspondingly low [21]. For example, the MIC value of the antifungal peptide P-1 with respect to *Trichothecium roseum* has been found to be as low as 1 µg/mL [22]. This is highly significant when it comes to improving the therapeutic effect of an antibacterial drug while reducing the dosage required.
| Microbial Species                  | Source           | Name of Antifungal Peptide       | Molecular Weight/Da | Fungal Species                                                                 | References |
|-----------------------------------|------------------|----------------------------------|---------------------|-------------------------------------------------------------------------------|------------|
| Bacillus BH072                    | Bacillus         | Flagellin                         | 35,615              | Aspergillus niger, Pythium, Botrytis cinerea, Fusarium oxysporum              | [23]       |
| Bacillus AH-E-1                    | Bacillus         | Not named                         | 500-1000            | A variety of plant and human pathogenic fungi                                | [24]       |
| Bacillus B9987                     | Bacillus         | Metabolites BMME-1                | Not mentioned       | Alternaria solani                                                             | [25]       |
| Bacillus subtilis                  | Bacillus         | Iturin A                          | 1095.5              | Candida, Hyphomycetes cerevisiae, Fusarium and Aspergillus                    | [26, 27]   |
| CCTCCM207209                       | Bacillus subtilis B25 | Not mentioned                        | 38708.67            | Fusarium oxysporum, Alternaria solani, Corynespora, Botrytis cinerea, Colletotrichum gloeosporioides | [28]       |
| Bacillus subtilis                  | Bacillus         | Subtilin, Iturin                  | 1042.6-1505.9       | Beauceria bassiana                                                           | [29]       |
| Bacillus cereus YQ 308             | Bacillus         | Chitinase, chitosanase, protease  | 48,000              | Fusarium oxysporum, Fusarium solani, Pythium ultimum                         | [30, 31]   |
| Bacillus thuringiensis S4          | Bacillus         | Chitin-binding protein CBP24      | 48,794.16           | Aspergillus                     | [32]       |
| Bacillus licheniformis W10         | Bacillus         | Serine protease                   | 1149.14             | Botrytis cinerea                                                             | [33]       |
| Bacillus pumilus HN-10             | Bacillus         | P-1                               | 1115                | Trichotheceum roseum                                                         | [34]       |
| Bacillus bereis DTU001              | Bacillus         | Not named                         | Not mentioned       | Candida, Penicillium, Aspergillus, etc.                                      | [35, 36]   |
| Paenibacillus polymyxza KT-8       | Paenibacillus     | Fusaricidin A                     | About 883           | Fusarium oxysporum, Aspergillus niger, Saccharomyces cerevisiae, M. griseola, etc | [37]       |
| Paenibacillus ehimensis MA2012      | Paenibacillus     | Not named                         | 1115                | A variety of plant pathogenic fungi, Colletotrichum                          | [37]       |
| Pseudomonas syringae               | Pseudomonas       | Syringostatin A, syringostatin E  | About 1179,7         | Yeasts, filamentous fungi                                                 | [38]       |
| Entrobacter pylori                 | Entrobacter       | HP 2-20                           | About 1161.3         | Candida albicans, Hyphomycoses burnetii                                       | [39]       |
| Enterococcus faecalis              | Enterococcus      | EntV                              | 3000-10,000         | C. albicans, C. tropicalis, C. paraplanatus, etc.                           | [39]       |
| Aspergillus nidulans               | Aspergillus       | Echinocandin B                    | About 1,060.2        | Candida                                                                       | [40]       |
| Aspergillus clavatus               | Aspergillus       | AcaFP                             | 5773                | Fusarium oxysporum, Aspergillus niger, Botrytis cinerea, etc.                | [40]       |
| Penicillium citrinum W1            | Penicillium       | PcPAF                             | About 10,000         | Trichoderma viride, Fusarium oxysporum, P. variotii,Alternaria longipes     | [41]       |
| Aureobasidium pullulans            | Aureobasidium     | Aureobasidin A(ABSA)              | 1070-1148           | Candida, Cryptococcus neoformans, Blastomyces dermatitisis, etc.             | [42, 43]   |
| Acremonium persicinum              | Acremonium        | VL-2397                           | About 914.9          | Aspergillus, Cryptococcus neoformans, Candida glabrata, etc.                | [44]       |
| Marine streptomyces DA11           | Streptomyces      | Chitinase                         | About 34,000        | Aspergillus niger, Candida albicans                                           | [45]       |
| Marine Actinomycetes M405           | Actinomycetes     | Chandranaminycin A                | About 270.24         | M. miehei                                                                    | [46]       |
| Actinomycete Streptomyces cacaoi    | Streptomyces      | Polyoxin D                        | About 521.4          | Candida albicans, Cryptococcus neoformans, etc.                              | [47]       |
| Streptomyces tendae                 | Streptomyces      | Nikkomycin Z                      | About 495.4          | Glomus, Aspergillus fumigatus, etc.                                          | [46, 49]   |
3. Stability of Antifungal Peptides

In general, the physical and chemical properties of the antifungal substances extracted from microbial fermentation broths (via separation and purification) need to be determined so that their stability can be ascertained and their suitability for antibacterial application decided. This mainly involves determining their structural stability to acidic/alkaline conditions and heat as well as with respect to various proteases, metal ions, chemical reagents, and ultraviolet (UV) light. Naturally, it is very helpful to ascertain the category to which the antifungal substance belongs (lipopeptide, polypeptide, protein, etc.). The properties of the substance thus determined clearly dictate the conditions required for its industrial production.

To determine the tolerance of the substance to acidic/alkaline environments, we need to ascertain the pH range over which the activity of the antifungal peptide is relatively stable. This range may be around neutral conditions [23], but there are also some results biased to acidic [50]/alkaline [51] conditions. Moreover, the highest antifungal activity is not always manifested in neutral solution. For example, the antifungal peptide PcPAF mentioned in Table 1 is most active in weakly acidic environments [41].

The highest temperature tolerated by most antifungal peptides corresponds to 100 °C [52,53]. However, Zhao et al. found active metabolites (produced by endophytic *Bacillus pallidus* ZZ185) that could maintain over 50% of their antifungal activity after exposure to 121 °C for 30 min [54].

Surfactants (e.g., sodium dodecyl sulfate and urea), organic compounds (e.g., ethylenediaminetetraacetic acid, trichloroacetic acid, chloroform), and ammonium sulfate are commonly used to test the stability of antifungal peptides. Researchers usually focus on antifungal peptides that are not sensitive to these chemicals [55]. Moreover, some active substances will show higher activity and stability in the presence of surfactants [56]. Many other chemical species are also commonly used when separating and purifying antifungal peptides and thus we also need to make sure the separation method chosen does not affect the activity of the antifungal component.

To test an antifungal substance for UV stability, the substance is irradiated with UV for different times and at different doses [57]. As for protease stability, the anti-degradation effect of the antifungal peptide on protease K, papain, pepsin, trypsin, etc. is often determined. The sensitivity of the different antifungal peptides to these substances is different, which is the main index used to judge the category to which the antifungal peptide belongs [22,28,58].

Metal ions (K⁺, Na⁺, Mg²⁺, Ca²⁺, Zn²⁺, Cu²⁺, etc.) also affect the activity of some antifungal peptides. Different ions have different effects on the same antifungal peptide, and the effect of the same ion on different antifungal peptides is not necessarily the same [53,59]. This reflects the different interactions that occur between the ions, fungi, and antimicrobial peptides, and such investigations can be of help when inferring the mechanism by which the antifungal peptide functions.

4. Toxicity of Antifungal Peptides

Once an antifungal species has been identified and its activity stability determined, its potential for further research and clinical application depends on its toxicity to the body. After all, one of the main disadvantages of some existing antifungal drugs is that they are highly toxic to the liver, kidneys, and/or blood. For example, the drugs traditionally used to treat deep invasive fungi (azole or polyene drugs) can lead to hepatotoxicity [60] or nephrotoxicity [61], causing extensive damage to different parts of the body under the action of multiple factors.

Echinocandins, e.g., caspofungin (a kind of lipopeptide antifungal substance) [62], on the other hand, are relatively safe to use in mammals because of their unique antifungal mechanism (acting as they do on the walls of the fungal cells). Compared with other antifungal drugs, these produce mild adverse reactions, including local phlebitis, fever, liver dysfunction, and mild hemolysis [63]. Moreover, these adverse reactions have been
gradually reduced in severity as these antifungal drugs have continued to be updated and improved [64].

Currently, the main adverse effect produced by certain antifungal peptides is hematotoxicity represented by erythrocyte hemolysis, which occurs to different degrees of severity. For example, pulmonary Candida albicans A0 has a high degree of hemolytic activity. Moreover, although it has effective fungicidal activity against Candida albicans, it lacks efficacy against some Aspergillus and other Candida species. Therefore, the practical application of pulmonary Candida albicans A0 needs to be given careful consideration [65].

It has also been reported that syringostatins A and E (isolated from Pseudomonas syringae) and iturin A (isolated from Bacillus subtilis) exhibit erythrotoxicity [21,66]. At the same time, the antifungal active lipopeptide extracted from Bacillus amyloliquefaciens SWB16 also has the iturin A gene, and thus it is possible that this antifungal substance will also exhibit erythrotoxicity [29]. Of course, some antifungal peptides (e.g., peptide Cm-p5) [67] and broad-spectrum antibacterial substances (e.g., AbA, residue 2–20 from Helicobacter pylori ribosomal protein and its analogues HPA3) [68,69] with low toxicity to mammals have been found.

In addition to hemolysis, antifungal peptides can also cause damage to DNA, e.g., actinomycin D (a member of the chromopeptide family) [70]. Although this substance has a significant effect on Verticillium wilt (which is caused by a fungal infection) [71], it can induce extensive and rapid apoptosis as it is widely recognized to be an inhibitor of RNA synthesis [72].

In this context, reduction or elimination of the toxicity of antifungal substances has long been an important issue. In addition to developing new varieties of antifungal peptides in order to find compounds with low toxicities, increasing numbers of researchers are focusing on structurally modifying existing antifungal substances or adding drug-loading systems to remove or hide their original toxicity. For example, echinocandin B is highly toxic to the blood of mammals as a result of its hemolytic behavior. In response, scientists have developed a semisynthetic analogue, cilofungin, which is significantly less toxic than echinocandin B [73]. The use of liposomes as a drug delivery system has also been found to perform well in anti-infection studies [74]. For example, when amphotericin B is administered as a liposomal formulation, its nephrotoxicity is significantly reduced, even though there is no significant change in its efficacy [61]. In addition, external solutions can be added to prevent hemolysis through appropriate osmotic protectants [66].

5. Mechanism of Action of Antifungal Peptides

Generally speaking, the mechanism by which antifungal peptides function is either to inhibit the growth and reproduction of the pathogen or to directly kill it. Depending on their target, they can be divided into three broad categories in which their action is aimed at: the pathogenic fungi, their own strains, or the cells of the host itself. It is also possible that new targets will be found for the drugs.

Knowledge of the mechanisms combined with the results of an analysis of the structure of the antifungal peptide provides a useful reference for the synthesis of new antifungal compounds with stronger antifungal activity, broader antibacterial spectra, and lower toxicity to the host. At present, however, our knowledge of the mechanisms by which antifungal peptides function is not complete. The following summarizes some of the widely recognized mechanisms by which antifungal peptides work.

5.1. Effect of Antifungal Peptides on Pathogenic Bacteria

From a macroscopic point of view, antifungal peptides inhibit or kill pathogenic fungi by inhibiting mycelial growth; affecting spore germination; or causing the hyphae or spores to become broken, swollen, twisted, or deformed, etc. Generally speaking, antifungal peptides have different effects on the survivability of pathogenic fungi. However, there are also antifungal peptides that only affect the morphology of the mycelium [39]. Bacillus AH-E-1 can distort the hyphae of Candida albicans and other fungi, and the antifungal
substances extracted from its fermentation supernatant can inhibit spore germination, germ tubes, and hyphal growth of filamentous fungi [24]. The antifungal peptide EP-2 produced by Bacillus subtilis E1R-J can swell and distort the mycelium of the fungi that causes apple canker, leading to the exosmosis of protoplasts, thus inhibiting the growth of the fungi [53]. The specific targets involved can be described in terms of the structure of the cells.

5.1.1. Targeting of Cell Walls

Antimicrobial peptides act on microbial cell walls via a characteristic mechanism that is different from that encountered using other antifungal drugs. This effectively avoids the problem of high toxicity to mammalian cells. The mechanism by which antifungal and antimicrobial peptides act on cell walls is different mainly because of the different components in their cell walls (mainly glycans) [75]. The cell walls of fungi are composed of carbohydrates (e.g., glucan), chitin, glycoproteins (e.g., mannoproteins), and various proteins [76]. It has been confirmed that some antifungal peptides can affect the synthesis of these main components, thus causing damage to the cell walls.

β-Glucans are the main polysaccharides in the cell walls of fungi. They have a network structure formed by connecting glucose monomers via β-(1,3)- or β-(1,6)-glycoside bonds. The network structure produced has a supporting effect on the cell walls and a variety of specific receptor sites on its surface are of great significance as they help the fungi to recognize and induce host immune responses [77]. Some antifungal peptides, e.g., echinocandins, are non-competitive inhibitors of β-(1,3)-glucan synthase, which affects the synthesis of fungal cell walls. This is the main way in which caspofungin [62], micafungin [78], and anifgin function. More specifically, the semisynthetic lipopeptide anifgin expresses its antibacterial activity by inhibiting the synthesis of (1,3)-β-D-glucan in the cell walls of Candida and Aspergillus, and this allows it to have an inhibitory effect on strains that are resistant to azole or polyene antifungal drugs [18]. In addition, studies have shown that some other compounds of the echinocandin family also function via the same mechanism of action [65,79]. The development and optimization of these compounds are thus promoting the development of new synthetic antifungal drugs for clinical use.

Chitin is an amino polysaccharide composed of N-acetyl-D-glucosamine units [80]. It is an important component of fungal cell walls and can therefore affect the regulation of cell viability and host immune response [81]. It has been found that changing the chitin content directly affects the sensitivity of some fungi to antifungal agents [82]. However, it cannot help the host to escape its fate completely. It has also been reported that although fungal chitin can induce and activate a variety of plant defense responses, the fungi can convert chitin into chitosan in the process of plant infection in order to escape the plant defense mechanisms [83]. Many antifungal substances extracted from Streptomyces species act on chitin. For example, Mizuhara et al. isolated cyclothiazomycin B1 from Streptomyces HA 125-40 that causes cell walls to rupture by binding with the chitin, leading to the death of fungal cells [84]. Other examples are nikkomycin and polyoxin, which are competitive inhibitors of chitin synthase [85,86] and have effect on many kinds of pathogenic bacteria [47,48,87]. A combination of nikkomycin Z and echinocandins has also been found to produce a synergistic effect against Aspergillus fumigatus [49], which is also related to their effect on chitin [82,88]. In addition to Streptomyces sources, the antifungal cyclic lipopeptide, chromobactomycin, which was obtained by Kim et al. from Chromobacterium C61 has also proved to be the key to the antibacterial effect of C61 according to in vitro experiments (by adding chitin to the medium) [89].

Mannan is found in the outermost layer of fungal cell walls. It can be glycosylated with proteins or peptides of different adhesion properties to form mannoprotein macromolecules. It has strong adhesive properties and determines the adhesion of the fungi to the host cells [90]. In addition, mannan also plays an important role in immune recognition and virulence of fungi [91]. The activity of the antifungal compound pradimicin (PRM) is aimed at cell wall mannan. Studies have shown that PRM can specifically recognize and bind
to the D-mannoside sites in the cell walls of Candida albicans forming a ternary complex of pradimicin, D-mannoside, and calcium, thus destroying the integrity of the fungal cell membrane and achieving an antifungal effect [92]. This mechanism endows it with broad-spectrum antifungal activity in vitro against Candida species, Cryptococcus neoformans, Aspergillus species, dematiaceous molds, etc. It also has no major end-organ toxicity and a good therapeutic index. It is the basis of a new class of antifungal compounds that are in preclinical and early, phase I clinical trials [92]. PRM can also induce cell apoptosis in Saccharomyces cerevisiae through the accumulation of reactive oxygen species [93] and it can also act on the N-glycosylation site of the osmotic-sensitive protein Sln1 and thus play a bactericidal role [94]. Benanomicin and other members of the same family have also been found to function via a similar antifungal mechanism (binding cell wall mannan sites) [95].

Microorganisms can also remove pathogenic fungi via physical adsorption. For example, polysaccharides, proteins, and lipids on the surfaces of cell walls can adsorb mycotoxins through hydrogen bonds, ionic bonds, and hydrophobic interactions, thus achieving detoxification [96]. Bejaoui et al. [97] found that Saccharomyces cerevisiae and S. bayanus yeasts can remove ochratoxin A from grape juice by physical adsorption. Furthermore, dead yeast cells gave a better adsorption effect than living yeast cells, which means the former can be used as a safe and effective method of biological detoxification.

5.1.2. Targeting Cell Membranes

To date, most of the antimicrobial peptides found in nature target cell membranes in order to exert their effects and a wide range of activities are involved. The realization of this action depends mainly on the physicochemical properties of antifungal peptides and target membrane tissues, which are the determinants of stable peptide–membrane interaction. For example, the electrostatic bonding between the antibacterial peptide and the surface structure of the target membrane due to the opposite charge will attract the antibacterial peptide to the cell membrane. Later, due to the amphiphilic nature of the antifungal peptides, they can combine with the lipid bilayer to form different secondary structures (such as α-helices, β-sheets, and so on). This is essential for the expression of their antibacterial activity. Only those peptides that can form highly amphiphilic structures have significant antibacterial activity [98], and the selectivity of different conformations to lipids is also different [99]. Moreover, Martins et al. discovered through the study on Trialysin that the selectivity of the active peptides for specific organisms appears to be associated with the structural features of their N- and C-termini [100]. In addition to these linear configurations, antibacterial peptides also commonly exhibit a circular conformation, forming a helix II structure, and intramolecular disulfide bonds play an important role in stabilizing the configuration [101]. In addition, hydrophilicity and hydrophobicity are also important properties of many antimicrobial peptides, which make antimicrobial peptides not only soluble in aqueous environment but also enter lipid rich membrane [102]. This property is closely related to the cytotoxicity and selectivity of antimicrobial peptides [103]. Researchers often modify natural antimicrobial peptides by hydroxylation, glycosylation, lipidization, and cyclization in order to optimize their properties (such as improving their stability and bioactivity) [104].

The research shows that there are two different physical models for the binding of antimicrobial peptides to lipid bilayers. The difference between them is the ratio of peptide to lipid (P/L) [105], which determines the sensitivity of cells to antimicrobial peptides. At low P/L, antimicrobial peptides tend to adsorb and embed into the lipid head base region in a state of functional inactivation and bind with lipid bilayers in parallel. With the increase of P/L ratio, the peptide began to act vertically on the membrane until it was inserted into the lipid bilayer to form a transmembrane pore (called state I) [105]. The ratio of type I peptide to lipid varies with the composition of peptide and target lipid, which can be described by three different action models [106].

Barrel wall model—In this model, helical peptides aggregate within the wall and form fascicular pores in the membrane with a central cavity, thus affecting the permeability
of the membrane [107]. Amphotericin B (AMB), a polyene antifungal agent, is the only natural product that produces an antifungal effect via this mechanism [108]. AMB targets membrane sterol, its antifungal activity reflected in the formation of transmembrane ion-permeable self-assemblies with ergosterol [109,110]. This mechanism provides a reasonable explanation for the selective toxicity of AMB [111]. This particular mode of intermolecular interaction has been verified in many experiments involving phospholipid monolayers [112] and bilayers [113], but the specific interaction mechanism needs to be studied further. It has also been found that fluconazole can reduce ergosterol content, and its combination with AMB can produce an antagonistic effect [114]. Interestingly, the glycotriazole peptides prepared by Junior et al. showed similar effects to fluconazole. The fungicidal activity of these peptides can be demonstrated by inhibiting ergosterol biosynthesis, which seems to be related to the presence of both the monosaccharide and the triazole rings [115].

_Carpet-like model_—In this model, the peptide covers the membrane surface in a carpet-like manner and interact with the membrane in parallel due to the electrostatic interaction with the anionic phospholipid head group. The formation of micelles at high peptide concentration destroys the phospholipid bilayer [116]. This mechanism makes lysate peptides can lyse cells of different microorganisms and normal mammalian cells [116], causing obvious toxicity problems. The syringomycin family of lipopeptides secreted by _Pseudomonas syringae_ belongs to this group. The transmembrane pores formed by these lipopeptides are permeable to cations and cause pathogen necrosis. The main reason for hemolysis is that it forms ion channels in the cell membrane and makes the colloids dissolve [117]. However, it has also been reported that the presence of cholesterol can reduce the binding of antimicrobial peptides to various lipid bilayer model membrane systems, thereby decreasing the lytic capacity of these peptide on the eukaryotic cells [118,119].

_Annular pore model_—In this model, a peptide helix is first inserted into the membrane to form a pore and the lipid monolayer is continuously bent until it passes through the membrane. The hydrophilic structure of the membrane then wraps the two sides to together forming a toroidal-shaped pore hole [120]. This mode of action has been widely verified in a variety of animal-derived antifungal peptides, such as melittin (found in bee venom) [121] and Xenopus antimicrobial peptide (found in Xenopus skin) [122].

There are many other antifungal peptides that exert their activity by interacting with membranes via mechanisms that are not yet fully understood. The lipopeptide iturin produced by _Bacillus_ species can interact with target cell membranes to form ion pores in the membrane, thus increasing the permeability of the pathogen cell membrane to potassium ions. The effective structure produced may be a ternary structure of the form iturin/phospholipid/sterol [123]. Actinomycin D can fold and split the plasma membranes of pathogenic fungi, destroying the membrane and leading to leakage of the cell contents [71].

Sphingolipids are also found in the plasma membranes of eukaryotic cells and are known to play important roles in cell growth, apoptosis, signal transduction, etc. [124]. The synthesis of inositol phosphoceramide (IPC) is a key step in the synthesis of sphingolipids in fungi. It has been shown that the cyclic non-ribosomal peptide aureobasidin that is produced by _Aureobasidium pullulans_ can inhibit sphingolipid synthesis by noncompetitive inhibition of IPC synthase, thus generating antibacterial action against _Candida_ species and _Cryptococcus neoformans_ [125]. Due to the lack of target enzymes in mammalian cells, it has also become a potential target for the development of non-toxic antifungal drugs. This has been verified in activity tests on IPC-synthase deficient mutants. The death of the mutant cells is accompanied by the accumulation of ceramide, suggesting that the existence of the ceramide activates the death response [126].

5.1.3. Targeting Nucleic Acids, Organelles, and Intracellular Macromolecules

The effects of antifungal peptides (on pathogenic fungi) are not limited to the destruction of the wall membranes. Rather, they can also affect the nuclei, organelles, and
intracellular proteins after entering the cells. Using various analytical methods (LC-HRMS analysis, Student’s t-test, etc.), Aspasia katragkou et al. [127] discovered a new mechanism of action of micafungin: by inhibiting the protein synthesis and cell replication of pathogenic fungi, it induces changes in their metabolic pathways.

Lee et al. studied the antifungal mechanism responsible for the action of a 14 helix β-peptide [128]. They found that after the β-peptide enters the cytoplasm (by interacting with the plasma membranes to form pores), it destroys the nucleus and vacuole, in turn leading to cell death. Through proteomic analysis and a series of validation tests, Han et al. determined the action pathway of the cyclic lipopeptide AMP-ja9 (produced by *Paenibacillus polymyxa* ja9) against *Fusarium moniliforme* [129]. The lipopeptide not only targets the cell membrane structure and enhances the leakage of potassium ions, proteins, and other components of the cytoplasm, but also regulates the levels of various intracellular proteins. It can thus strongly affect the normal life activities of the cells, affecting their structure and metabolism.

In addition to the above mechanisms, the special structures of some antifungal peptides also determine their unique antibacterial pathways. For example, a new type of *Aspergillus*-resistant, aluminum-chelating, cyclic hexapeptide VL-2397 (formerly known as ASP2397) has recently attracted much attention [130]. Its structure is similar to that of a ferrichrome-type siderophore (which can absorb iron from the outside through the iron carrier transporter on the cell membrane). The xylose-dependent iron carrier transporter gene *sit1* occurs in the plasma membrane of some *Aspergillus* species, e.g., *A. fumigatus* and *A. flavus*, and the expression of this gene determines the uptake of VL-2397 by the *Aspergillus* species [130]. The interaction between VL-2397 and intracellular targets inhibits mycelial elongation, thus achieving an antibacterial effect. As mammalian cells do not contain the corresponding genes, the antifungal peptide has good prospects for use in clinical applications [131].

5.2. Effects of Antifungal Peptides on Their Own Strains

Antifungal peptides can also affect cluster movement and the colonization and biofilm formation ability of some bacterial strains. They can thus promote the mass propagation or colonization of bacteria in plant roots, which can inhibit the growth of pathogenic fungi and thus protect the plant [132]. Experiments have shown that bacillomycin D produced by the rhizosphere strain *Bacillus amyloliquefaciens* SQR9 plays a vital role in the antagonistic activity of SQR9 against *Fusarium oxysporum* [133]. This was confirmed by testing the antagonistic activity of mutant species lacking this lipopeptide. In addition, the bacillomycin D was found to improve the expression level of the *kinC* gene, which promotes biofilm formation and the growth and colonization of the SQR9 itself, helping to prevent the *F. oxysporum* from causing plant wilt.

5.3. Competitive Effects of Antifungal Peptides on Host Targets and Nutrients

In addition to antibacterial activity, antimicrobial peptides have been found that can interact directly with host cells by modulating the inflammatory and innate defense mechanisms [134]. For example, through regulation of the expression of plant proteins and metabolism level, it is possible to strengthen the plant’s defense system, promoting growth and inducing positive changes in its disease resistance and physiological function [135–137]. In this way, *Trichoderma* strains can interact with olive leaf spot and the pathogenic fungi of olive leaf spot to produce secondary metabolites, induce the expression of defense-related genes, and enhance the disease resistance of the plants [138].

At the same time, many growth-promoting bacteria occupy the same action sites on plants as pathogenic fungi. Therefore, both compete for the nutrients secreted by the plants and already present in the environment. This can be used to inhibit, or even eliminate, the pathogenic fungi, an approach that has been widely used in plant disease control [139]. *Metschnikowia citriensis* strain FL01 exerts a biocontrol effect on citrus sour rot in citrus fruit by rapidly colonizing wounds on the fruit and competing for nutrition and space with
the pathogenic fungi [140]. It promotes biofilm formation in the citrus fruit and inhibits mycelium growth and spore germination. However, it cannot produce cell metabolites or volatile organic compounds that have antibacterial effects. Cryptococcus laurentii, on the other hand, also has an antagonistic ability towards this pathogen that can be attributed to its competing for the same nutrients and space, its defense responses, and its ability to secret antibiotics [141].

5.4. Brief Summary

Figure 1 summarizes the mechanism of some antifungal peptides mentioned above. There are several antimicrobial pathways, such as oxidative stress, osmotic stress, apoptosis, destruction of cytoskeleton structure, and cell metabolism disorder. It is not difficult to see that most antifungal peptides rely on a single antibacterial mechanism. However, they often act on a variety of structures and combine a variety of ways to achieve their antibacterial purpose. For example, iturin can induce oxidative stress through the accumulation of reactive oxygen species and can interact with target cell membranes to regulate protein levels, which can lead to cell wall rupture. Moreover, cytoplasmic extravasation caused by cell rupture can also induce cell osmotic stress. In addition, it can also act as an activator to induce plant defense response to pathogenic fungi [142]. These pathways play an important role in the antibacterial activity of iturin. However, the accumulation of reactive oxygen species and osmotic stress also activate the HOG-MAPK pathway, which can resist the damage of oxidative stress and osmotic stress. This pathway may be related to fungal drug resistance [142].

The effects of fengycin on some Candida and Rhizopus species are also manifested in many ways, such as the destruction of pathogen cell walls; inhibition of DNA synthesis; and apoptosis marked by accumulation of reactive oxygen species, mitochondrial dysfunction, and phosphatidylserine eversion [143,144]. Some Bacillus species produce lipopeptides called surfactins that are highly potent biosurfactants that have similar anti-Candida and anti-Fusarium moniliforme activities to fengycin [145]. The combined effect of surfactin and fengycin has been studied but the results achieved were not ideal [146]. However, combination therapy, especially in the context of traditional antifungal drugs, has long been a way of obtaining better antifungal effects. For example, Gupta et al. found that miconazole and fluconazole combined with a low dose of amiodarone has a strongly synergistic fungicidal effect [147]. They also found that amiodarone by itself can produce an antibacterial effect by destroying calcium homeostasis in Saccharomyces cerevisiae cells. Thus, it is potentially an effective antibacterial drug that can also bring new vitality to traditional antifungal drugs.

Figure 1A shows the mechanism of some antifungal peptides. Pradimycin, amphotericin B, and fengycin can induce apoptosis through the accumulation of ROS. In addition, pradimycin can also bind to the transmembrane protein sln1 to induce apoptosis. Itulin and C16-FengycinA can not only accumulate ROS to induce oxidative stress, but also damage the cell wall to cause cytoplasmic extravasation to induce osmotic stress. However, the activated HOG-MAPK pathway can resist this oxidative stress and osmotic stress. In addition, iturin can directly affect the activity of pathogens by inhibiting cell wall integrity. AMP-jsa9 can inhibit the synthesis of the cell membrane and cell wall of pathogenic bacteria, destroy the cytoskeleton, and affect the normal life activities of pathogenic bacteria by regulating the expression of related proteins. Figure 1B shows two models of destruction of cell membrane by microbial antifungal peptides. Carpet-like model (syringomycin family of lipopeptides): the attached peptides aggregate and insert into the membrane so that the hydrophobic region is aligned with the lipid, and the hydrophilic region is inward to form pores. Barrel wall model (amphotericin B): the peptide forms a large layer parallel to the membrane surface to destroy the membrane. Figure 1C shows the main membrane structure of pathogenic fungi affected by antimicrobial peptides. C16-FengycinA can reduce the hydrophobicity of pathogen and inhibit the synthesis of glucan and chitin, Amp-jsa9 can destroy the cytoskeleton and reduce the content of chitin and ergosterol, and
Aureobasidin can inhibit the synthesis of sphingolipids. The decrease of the content of these substances is related to the downregulation of the expression of related proteins by antimicrobial peptides.

![Figure 1. Action pathways and mechanisms of action of some antifungal peptides. (A) the mechanism of some antifungal peptides; (B) two models of destruction of cell membrane by mi-crobial antifungal peptides; (C) the main membrane structure of pathogenic fungi affected by antimicrobial peptides.](image)

6. Expectations

Future research should focus on exploring new antifungal peptide resources and developing further antifungal microorganisms with excellent activity and low toxicity. It
will be necessary to screen and purify the antifungal peptides discovered, determine their structure–activity relationships, and find ways to artificially synthesize them. Naturally occurring antifungal peptides can be structurally modified using genetic engineering techniques and bioinformatics, so as to obtain antifungal peptides that are more efficient, stable, and safe. From the point of view of treating fungal infections, the development of drug delivery systems and use of new drug combinations are important directions to explore. The overall aim must be to develop antifungal biological agents that are more suitable for use in clinical prevention and treatment applications.

**Author Contributions:** Writing—original draft preparation, T.L.; writing—review and editing, F.D., L.L., L.S. and J.S.; supervision, M.L. and Z.C. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was financially supported by the National Natural Science Foundation of China (grant no. 31872538, grant no. 31972746, grant no. 31772809) and Liaoning Provincial Natural Fund Guidance Program Project (2019-ZD-0708). This work was also supported by the National Key Research and Development Program Projects of China (2017YFD0500305, 2017YFD0500901), the National Key Program for Infectious Disease of China (2018ZX10101002-002), the State Key Program of National Natural Science of China (U1808202), NSFC International (regional) cooperation and exchange program (31961143024), and major science and technology projects of Inner Mongolia of China.

**Data Availability Statement:** Data availability in this paper.

**Acknowledgments:** We thank Shenyang Agricultural University for supporting this work.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Shentsova, E.S.; Lytkina, L.I.; Shevtsov, A.A. Reduction of the content of aflatoxin-forming fungi in contaminated grains by methods of hydrothermal treatment. *Gig. I Sanit.* 2015, 94, 64–67.
2. Lestrade, P.P.; Bentvelsen, R.G.; Schauwvlieghe, A.; Schalekamp, S.; van der Velden, W.; Kuiper, E.J.; van Paassen, J.; van der Hoven, B.; van der Lee, H.A.; Melechers, W.J.G.; et al. Voriconazole Resistance and Mortality in Invasive Aspergillosis: A Multicenter Retrospective Cohort Study. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* 2019, 68, 1463–1471. [CrossRef] [PubMed]
3. Martel, C.M.; Parker, J.E.; Bader, O.; Weig, M.; Gross, U.; Warrilow, A.G.; Kelly, D.E.; Kelly, S.L. A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B. *Antimicrob. Agents Chemother.* 2010, 54, 3578–3583. [CrossRef] [PubMed]
4. Farahyar, S.; Zaini, F.; Kordbacheh, P.; Rezaie, S.; Safari, M.; Raoofian, R.; Heidari, M. Overexpression of aldo-keto-reductase in azole-resistant clinical isolates of Candida glabrata determined by cDNA-AFLP. *Daru J. Fac. Pharm. Tehran Univ. Med. Sci.* 2013, 21, 1. [CrossRef]
5. Fan, X.; Xiao, M.; Liao, K.; Kudinha, T.; Wang, H.; Zhang, L.; Hou, X.; Kong, F.; Xu, Y.C. Notable Increasing Trend in Azole and Clinical Azole Consumption. *Front. Microbiol.* 2017, 8, 464. [CrossRef]
6. Fisher, M.C.; Hawkins, N.J.; Sanglard, D.; Gurr, S.J. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. *Science* 2018, 360, 739–742. [CrossRef]
7. Bahar, A.A.; Ren, D. Antimicrobial peptides. *Pharmaceuticals* 2013, 6, 1543–1575. [CrossRef]
8. Steiner, H.; Hultmark, D.; Engström, A.; Bennich, H.; Boman, H.G. Sequence and specificity of two antibacterial proteins involved in insect immunity. *Nature* 1981, 292, 246–248. [CrossRef]
9. Fry, D.E. Antimicrobial Peptides. *Surg. Infect.* 2018, 19, 804–811. [CrossRef]
10. Landy, M.; Warren, G.H.; RosenmanM, S.B.; Colio, L.G. Bacillomycin: An antibiotic from Bacillus subtilis active against pathogenic fungi. Proceedings of the Society for Experimental Biology and Medicine. *Soc. Exp. Biol. Med.* 1948, 67, 539–541. [CrossRef]
11. Banerjee, N.; Bose, S.K. Mode of action of mycobacin, a new antifungal antibiotic. *J. Bacteriol.* 1963, 86, 387–391. [CrossRef] [PubMed]
12. Banerjee, A.B.; Bose, S.K. Biosynthesis of mycobacin, a new antifungal peptide. i. role of nucleic acid. *J. Bacteriol.* 1964, 87, 1397–1401. [CrossRef] [PubMed]
13. Boman, H.G. Antibacterial peptides: Key components needed in immunity. *Cell* 1991, 65, 205–207. [CrossRef]
14. Li, X.; Zhang, Y.; Wei, Z.; Guan, Z.; Cai, Y.; Liao, X. Antifungal Activity of Isolated Bacillus amyloliquefaciens SYBC H47 for the Biocontrol of Peach Gummosis. *PLoS ONE* 2016, 11, e0162125. [CrossRef] [PubMed]
15. Nyfeler, R.; Keller-Schierlein, W. Metabolites of microorganisms. 143. Echinocandin B, a novel polypeptide-antibiotic from Aspergillus nidulans var. echinulatus: Isolation and structural components. *Helv. Chim. Acta* **1974**, *57*, 2459–2477. [CrossRef] [PubMed]

16. Manivasagan, P.; Venkatesan, J.; Sivakumar, K.; Kim, S.K. Pharmaceutically active secondary metabolites of marine actinobacteria. *Microbiol. Res.* **2014**, *169*, 262–278. [CrossRef] [PubMed]

17. Zhao, P.; Xue, Y.; Gao, W.; Li, J.; Zu, X.; Fu, D.; Feng, S.; Bai, X.; Zuo, Y.; Li, P. Actinobacteria-Derived peptide antibiotics since 2000. *Peptides* **2018**, *103*, 48–59. [CrossRef] [PubMed]

18. Martín Mazuelos, E.; Rodríguez-Tudela, J.L. In vitro activity of anidulafungin. Comparison with the activity of other echinocandins. *Enferm. Infecc. y Microbiol. Clin.* **2008**, *26*, 7–13. [CrossRef]

19. Yao, J.; Liu, H.; Zhou, T.; Chen, H.; Miao, Z.; Sheng, C.; Zhang, W. Total synthesis and structure-activity relationships of new echinocandin-like antifungal cyclolipohexapeptides. *Eur. J. Med. Chem.* **2012**, *50*, 196–208. [CrossRef] [PubMed]

20. Zhao, Y.; Perlin, D.S. Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data. *J. Fungi* **2020**, *6*, 192. [CrossRef]

21. Sorensen, K.N.; Kim, K.H.; Takemoto, J.Y. In vitro antifungal and fungicidal activities and erythrocyte toxicities of cyclic lipopepsinonapeptides produced by *Pseudomonas syringae* pv. syringae. *Antimicrob. Agents Chemother.* **1996**, *40*, 2710–2713. [CrossRef] [PubMed]

22. Yan, H.; Yun, J.; Ai, D.; Zhang, W.; Bai, J.; Guo, J. Two novel cationic antifungal peptides isolated from *Bacillus pumilus* HN-10 and their inhibitory activity against *Trichothecium roseum*. *World J. Microbiol. Biotechnol.* **2018**, *34*, 21. [CrossRef] [PubMed]

23. Zhao, X.; Zhou, Z.J.; Han, Y.; Wang, Z.Z.; Fan, J.; Xiao, H.Z. Isolation and identification of antifungal peptides from *Bacillus* BH072, a novel bacterium isolated from honey. *Microbiol. Res.* **2013**, *168*, 598–606. [CrossRef] [PubMed]

24. Chen, N.; Jin, M.; Qu, H.M.; Chen, Z.Q.; Qiu, Z.G.; Wang, X.W.; Li, J.W. Isolation and characterization of *Bacillus* sp. producing broad-spectrum antibiotics against human and plant pathogenic fungi. *J. Microbiol. Biotechnol.* **2012**, *22*, 256–263. [CrossRef]

25. Gao, W.; Tian, L.; Zhou, J.; Shi, Z.; Zheng, L.; Cui, Z.; Li, Y. Antifungal mechanism of *Bacillus* marinus B-9987. *Wei Sheng Wu Xue Bao = Acta Microbiol. Sin.* **2009**, *49*, 1494–1501.

26. Lei, S.; Zhao, H.; Pang, B.; Qu, R.; Lian, Z.; Jiang, C.; Shao, D.; Huang, Q.; Jin, M.; Shi, J. Capability of iturin from *Bacillus subtilis* in inhibiting *Candida albicans* in vitro and in vivo. *Appl. Microbiol. Biotechnol.* **2019**, *103*, 4377–4392. [CrossRef] [PubMed]

27. Klich, M.A.; Lax, A.R.; Bland, J.M. Inhibition of some mycotoxigenic fungi by iturin A, a peptidolipid produced by *Bacillus* subtilis. *Mycopathologia* **2001**, *143*, 116, 111–70. [CrossRef]

28. Tan, Z.; Lin, B.; Zhang, R. A novel antifungal protein of *Bacillus subtilis* B25. *SpringerPlus* **2013**, *2*, 543. [CrossRef]

29. Wang, J.; Zhao, D.; Liu, Y.; Ao, X.; Fan, R.; Duan, Z.; Liu, Y.; Chen, Q.; Jin, Z.; Wan, Y. Antagonism against *Beauveria bassiana* by *Bacillus* sp. producing antifungal substances against human and plant pathogenic fungi. *J. Microbiol. Biotechnol.* **2012**, *22*, 256–263. [CrossRef]

30. Chang, W.T.; Chen, C.S.; Wang, S.L. An antifungal chitinase produced by *Bacillus cereus* with shrimp and crab shell powder as a carbon source. *Curr. Microbiol.* **2003**, *47*, 102–108. [CrossRef]

31. Chang, W.T.; Chen, Y.C.; Jao, C.L. Antifungal activity and enhancement of plant growth by *Bacillus* cereus grown on shellfish chitin wastes. *Bioresour. Technol.* **2007**, *98*, 1224–1230. [CrossRef] [PubMed]

32. Mehmood, M.A.; Latif, M.; Hussain, K.; Gull, M.; Latif, F.; Rajoka, M.I. Heterologous expression of the antifungal β-chitin binding protein CBP24 from *bacillus thuringiensis* and its synergistic action with bacterial chitinases. *J. Fungi* **2013**, *9*, 21. [CrossRef] [PubMed]

33. Ji, Z.L.; Peng, S.; Chen, L.L.; Liu, Y.; Yan, C.; Zhu, F. Identification and characterization of a serine protease from *Bacilluslicheniformis* W10: A potential antifungal agent. *Int. J. Biol. Macromol.* **2020**, *155*, 594–603. [CrossRef]

34. Devi, S.; Kiesewalter, H.T.; Kovács, R.; Frisvad, J.C.; Weber, T.; Larsen, T.O.; Kovác, Á.T.; Deng, L. Depiction of secondary metabolites and antifungal activity of *Bacillus velezensis* DTU001. *Synth. Syst. Biotechnol.* **2019**, *4*, 142–149. [CrossRef] [PubMed]

35. Kajimura, Y.; Kaneda, M. Fusaricin A, a new depsipeptide antibiotic produced by *Bacillus polymyxa* KT-8. Taxonomy, fermentation, isolation, structure elucidation and biological activity. *J. Antibiot.* **1996**, *49*, 129–135. [CrossRef] [PubMed]

36. Hua, B.; Feng, H.; Han, J.; Qiao, Z.; Wang, X.; Zhang, Q.; Liu, Z.; Wu, Z. Isolation and Characterization of a New Fusaricidin-Type Antibiotic Produced by *Paenibacillus bovis* sp. nov. *BD3526*. *Curr. Microbiol.* **2020**, *77*, 3990–3999. [CrossRef] [PubMed]

37. Naing, K.W.; Lee, Y.S.; Nguyen, X.H.; Jeong, M.H.; Anees, M.; Oh, B.S.; Cho, J.Y.; Moon, J.H.; Kim, K.Y. Isolation and characterization of an antimicrobial lipopeptide produced by *Paenibacillus ehimensis* MA2012. *J. Basic Microbiol.* **2015**, *55*, 857–868. [CrossRef]

38. Ribeiro, P.D.; Medina-Acosta, E. Prevention of lethal murine candidiasis using HP (2-20), an antifungal peptide derived from the N-terminus of Helicobacter pylori ribosomal protein L1. *Peptides* **2003**, *24*, 1807–1814. [CrossRef]

39. Graham, C.E.; Cruz, M.R.; Garsin, D.A.; Lorenz, M.C. Enterococcus faecalis bacteriocin EntV inhibits hyphal morphogenesis, biofilm formation, and virulence of *Candida albicans*. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, 4507–4512. [CrossRef]

40. Skouri-Gargouri, H.; Gargouri, A. First isolation of a novel thermostable antifungal peptide secreted by *Aspergillus clavatus*. *Peptides* **2008**, *29*, 1871–1877. [CrossRef]

41. Wen, C.; Guo, W.; Chen, X. Purification and identification of a novel antifungal protein secreted by *Penicillium citrinum* from the Southwestern Indian Ocean. *J. Microbiol. Biotechnol.* **2014**, *24*, 1337–1345. [CrossRef]
42. Takesako, K.; Kuroda, H.; Inoue, T.; Haruna, F.; Yoshikawa, Y.; Kato, I.; Uchida, K.; Hiritani, T.; Yamaguchi, H. Biological properties of aureobasidin A, a cyclic depsipeptide antifungal antibiotic. *J. Antibi*. **1993**, *46*, 1414–1420. [CrossRef]

43. Takesako, K.; Ikai, K.; Haruna, F.; Endo, M.; Shimanka, K.; Sono, E.; Nakamura, T.; Kato, I.; Yamaguchi, H. Aureobasidins, new antifungal antibiotics. Taxonomy, fermentation, isolation, and properties. *J. Antibi*. **1991**, *44*, 919–924. [CrossRef] [PubMed]

44. Nakamura, I.; Yoshimura, S.; Masaki, T.; Takase, S.; Ohsumi, K.; Hashimoto, M.; Furukawa, S.; Fujie, A. ASP2397: A novel antifungal agent produced by Accrementum persici MF-34783. *J. Antibi*. **2017**, *70*, 45–51. [CrossRef] [PubMed]

45. Han, Y.; Yang, B.; Zhang, F.; Miao, X.; Li, Z. Characterization of antifungal chitinase from marine Streptomyces sp. DA11 associated with South China Sea sponge Cranisella australiensis. *Mar. Biotechnol.* **2009**, *11*, 132–140. [CrossRef]

46. Maskey, R.P.; Li, F.; Qin, S.; Feigb, H.H.; Laatsch, H. Chandrananymycins A approximately C: Production of novel anticancer antibiotics from a marine Actinomadura sp. isolate M048 by variation of medium composition and growth conditions. *J. Antibi*. **2003**, *56*, 622–629. [CrossRef]

47. Becker, J.M.; Covert, N.L.; Shenbagamurthi, P.; Steinfeld, A.S.; Naider, F. Polyoxin D inhibits growth of zoopathogenic fungi. *Antimicrob. Agents Chemother.* **1983**, *23*, 926–929. [CrossRef]

48. Hector, R.F.; Zimmer, B.L.; Pappagianis, D. Evaluation of nikkomyins X and Z in murine models of coccidiodiomycosis, histoplasmosis, and blastomycosis. *Antimicrob. Agents Chemother.* **1990**, *34*, 587–593. [CrossRef]

49. Ganesan, L.T.; Manavathu, E.K.; Cutright, J.L.; Alangaden, G.J.; Chandrasekar, P.H. In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus. *Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis.*** **2004**, *10*, 961–966. [CrossRef] [PubMed]

50. Rong, S.; Xu, H.; Li, L.; Chen, R.; Gao, X.; Xu, Z. Antifungal activity of endophytic Bacillus safensis B21 and its potential application as a biopesticide to control rice blast. *Pestic. Biochem. Physiol.* **2020**, *162*, 69–77. [CrossRef]

51. Seyedjavadi, S.S.; Khani, S.; Zare-Zardini, H.; Halabian, R.; Goudarzi, M.; Khatami, S.; Imani Fooladi, A.A.; Amani, J.; Razzaghi-Abyaneh, M. Isolation, functional characterization, and biological properties of MCh-AMP1, a novel antifungal peptide from *Matriaria chamomilla* L. *Chin. Biol. Drug Des.*** **2019**, *93*, 949–959. [CrossRef] [PubMed]

52. Zhang, Q.X.; Zhang, Y.; Shan, H.H.; Tong, Y.H.; Chen, X.J.; Liu, F.Q. Isolation and identification of antifungal peptides from Bacillus amyloquefaciens W10. *Environ. Sci. Pollut. Res. Int.* **2017**, *24*, 25000–25009. [CrossRef]

53. Wang, N.N.; Yan, X.; Gao, X.N.; Niou, H.J.; Kang, Z.S.; Huang, L.L. Purification and characterization of a potential antifungal protein from Bacillus subtilis EIR1 against Valsa mali. *World J. Microbiol. Biotechnol.* **2016**, *32*, 63. [CrossRef]

54. Zhao, Z.; Wang, Q.; Wang, K.; Bria, K.; Liu, C.; Gu, Y. Study of the antifungal activity of Bacillus vallismortis ZZ185 in vitro and identification of its antifungal components. *Bioresour. Technol.* **2010**, *101*, 292–297. [CrossRef]

55. Ramachandran, R.; Chalasani, A.G.; Lal, R.; Roy, U. A broad-spectrum antimicrobial activity of Bacillus subtilis RLID 12.1. *Sci. World J.* **2014**, *2014*, 968487. [CrossRef]

56. Schmidt, G.; Krings, U.; Nintz, M.; Berger, R.G. A surfactant tolerant laccase of Meripilus giganteus. *World J. Microbiol. Biotechnol.* **2012**, *28*, 1623–1632. [CrossRef]

57. Shokri, D.; Zaghian, S.; Khodabakhshi, F.; Fazeli, H.; Mobasherizadeh, S.; Ataei, B. Antimicrobial activity of a UV-stable bacteriocin-like inhibitory substance (BLIS) produced by Enterococcus faecium strain DSH20 against vancomycin-resistant Enterococcus (VRE) strains. *J. Microbiol. Immunol. Infect. Wei Mian Yu Gan Ran Za Zhi*** **2014**, *47*, 371–376. [CrossRef]

58. Wu, S.; Jia, S.; Sun, D.; Chen, M.; Chen, X.; Zhong, J.; Huan, L. Purification and characterization of two novel antimicrobial peptides Subpeptin JM4-A and Subpeptin JM4-B produced by Bacillus subtilis JM4. *Curr. Microbiol.* **2005**, *51*, 292–296. [CrossRef] [PubMed]

59. Schmidt, M.; Arendt, E.K.; Thery, T.L. Isolation and characterisation of the antifungal activity of the cowpea defensin Cp-thionin II. *Food Microbiol.* **2019**, *82*, 504–514. [CrossRef] [PubMed]

60. Tverdek, F.P.; Kofteridis, D.; Kontoyiannis, D.P. Antifungal agents and liver toxicity: A complex interaction. *Expert Rev. Anti-Infect. Ther.* **2016**, *14*, 765–776. [CrossRef]

61. Hamill, R.J. Amphotericin B formulations: A comparative review of efficacy and toxicity. *Drugs*** **2013**, *73*, 919–934. [CrossRef] [PubMed]

62. Chandrasekar, P.H.; Manavathu, E.K. Kasposfungin. *Drugs Today*** **2002**, *38*, 829–846. [CrossRef]

63. Denning, D.W. Echinocandin antifungal drugs. *Lancet*** **2000**, *356*, 1142–1151. [CrossRef]

64. Hector, R.F.; Bierer, D.E. New β-glucan inhibitors as antifungal drugs. *Expert Opin. Ther. Pat.* **2011**, *21*, 1597–1610. [CrossRef]

65. Debono, M.; Gordee, R.S. Antibiotics that inhibit fungal cell wall development. *Annu. Rev. Microbiol.* **1994**, *48*, 471–497. [CrossRef]

66. Aranda, F.J.; Teruel, J.A.; Ortiz, A. Further aspects on the hemolytic activity of the antibiotic lipopeptide iturin A. *Biochim. Et Biophys. Acta*** **2005**, *1713*, 51–56. [CrossRef] [PubMed]

67. López-Abarrategui, C.; McBeth, C.; Mandal, S.M.; Sun, Z.J.; Heffron, G.; Alba-Menéndez, A.; Migliolo, L.; Reyes-Acosta, O.; García-Villarino, M.; Nolasco, D.O.; et al. Cm-p5: A novel antifungal hydrophilic peptide derived from the coastal mollusk Cenchritis muricatus (Gastropoda: Littorinidae). *FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol.* **2015**, *29*, 3315–3325. [CrossRef]

68. Park, S.C.; Kim, M.H.; Hossain, M.A.; Shin, S.Y.; Kim, Y.; Stella, L.; Wade, J.D.; Park, Y.; Hahn, K.S. Amphipathic alpha-helical peptide, HP (2-20), and its analogues derived from Helicobacter pylori: Pore formation mechanism in various lipid compositions. *Biochim. Biophys. Acta*** **2008**, *1778*, 229–241. [CrossRef]

69. Heidler, S.A.; Radding, J.A. Inositol phosphoryl transferases from human pathogenic fungi. *Biochim. Biophys. Acta*** **2000**, *1500*, 147–152. [CrossRef]
70. Yamamoto, K.N.; Hirota, K.; Kono, K.; Takeda, S.; Sakamuru, S.; Xia, M.; Huang, R.; Austin, C.P.; Witt, K.L.; Tice, R.R. Characterization of environmental conditions with potential for DNA damage using isogenic DNA repair-deficient chicken DT40 cell lines. *Environ. Mol. Mutagenesis* 2011, 52, 547–561. [CrossRef]

71. Zeng, H.; Feng, P.X.; Wan, C.X. Antifungal effects of actinomycin D on Verticillium dahliae via a membrane-splitting mechanism. *Nat. Prod. Res.* 2019, 33, 1751–1755. [CrossRef]

72. Kumarswamy, R.; Chandana, S. Inhibition of microRNA-14 contributes to actinomycin-D-induced apoptosis in the Sf9 insect cell line. *Cell Biol. Toxicol.* 2010, 34, 851–857. [CrossRef]

73. Debono, M.; Abbott, B.J.; Turner, J.R.; Howard, L.C.; Gordee, R.S.; Hunt, A.S.; Barnhart, M.; Molloy, R.M.; Willard, K.E.; Fukuda, D.; et al. Synthesis and evaluation of LY121019, a member of a series of semisynthetic analogues of the antifungal lipopeptide echinocandin B. *Ann. N. Y. Acad. Sci.* 1988, 544, 152–167. [CrossRef] [PubMed]

74. Allen, T.M.; Cullis, P.R. Liposomal drug delivery systems: From concept to clinical applications. *Adv. Drug Deliv. Rev.* 2013, 65, 36–48. [CrossRef] [PubMed]

75. Jenssen, H.; Hamill, P.; Hancock, R.E. Peptide antimicrobial agents. *Clin. Microbiol. Rev.* 2006, 19, 491–511. [CrossRef] [PubMed]

76. Garcia-Rubio, R.; de Oliveira, H.C.; Rivera, J.; Trevijano-Contador, N. The Fungal Cell Wall: Candida, Cryptococcus, and Aspergillus Species. *Front. Microbiol.* 2019, 10, 2993. [CrossRef]

77. Akramiene, D.; Kondrotas, A.; Didziapetriene, J.; Kevelaitis, E. Effects of beta-glucans on the immune system. *Medicina* 2007, 43, 597–606. [CrossRef]

78. Wasmann, R.E.; Muilwijk, E.W.; Burger, D.M.; Verweij, P.E.; Knibbe, C.A.; Brüggemann, R.J. Clinical Pharmacokinetics and Pharmacodynamics of Micafungin. *Clin. Pharm.* 2019, 57, 267–286. [CrossRef] [PubMed]

79. Li, Y.; Lan, N.; Xu, L.; Yue, Q. Biosynthesis of pneumocandin lipopeptides and perspectives for its production and related echinocandins. *Appl. Microbiol. Biotechnol.* 2018, 102, 9881–9891. [CrossRef] [PubMed]

80. Cohen, E. Chitin synthesis and inhibition: A revisit. *Antimicrob. Agents Chemother.* 2015, 59, 146–154. [CrossRef] [PubMed]

81. Plaza, V.; Silva-Moreno, E.; Castillo, L. Breakpoint: Cell Wall and Glycoproteins and their Crucial Role in the Phytopathogenic Aspergillus Species. *Front. Microbiol.* 2014, 2894–2904. [CrossRef] [PubMed]

82. Walker, L.A.; Gow, N.A.; Munro, C.A. Elevated chitin content reduces the susceptibility of Candida species to caspofungin. *Antimicrob. Agents Chemother.* 2013, 57, 146–154. [CrossRef] [PubMed]

83. Akramiene, D.; Kondrotas, A.; Didziapetriene, J.; Kevelaitis, E. Effects of beta-glucans on the immune system. *Medicina* 2007, 43, 597–606. [CrossRef]

84. Zhang, D.; Miller, M.J. Polyoxins and nikkomycins: Progress in synthetic and biological studies. *J. Fungi* 2020, 6, 261. [CrossRef] [PubMed]

85. Herman, J.; Alas, Z.; Aksamit, E.; Skowrońska, L.; Sadowska, B.; Nowak, G.; Kuch, M.; Maćkowiak, K.; Niemiec, M.; et al. Echinocandin B. *Molecules* 2017, 22, 1751–1755. [CrossRef] [PubMed]

86. Fernandes, C.; Anjos, J.; Walker, L.A.; Silva, B.M.; Cortes, L.; Mota, M.; Munro, C.A.; Gow, N.A.; Brüggemann, R.J. Clinical Pharmacokinetics and Pharmacodynamics of Micafungin. *Clin. Pharm.* 2019, 57, 267–286. [CrossRef] [PubMed]

87. Li, Y.; Lan, N.; Xu, L.; Yue, Q. Biosynthesis of pneumocandin lipopeptides and perspectives for its production and related echinocandins. *Appl. Microbiol. Biotechnol.* 2018, 102, 9881–9891. [CrossRef] [PubMed]

88. Bravo, D.; González, B.; García, A.; Varela, D.; García-Rubio, R.; de Oliveira, H.C.; García, P. Fatty acid composition of cell wall lipids of C. tropicalis and C. krusei. *FEMS Microbiol. Lett.* 2019, 364, 1–9. [CrossRef] [PubMed]

89. Garcia-Rubio, R.; de Oliveira, H.C.; Rivera, J.; Trevijano-Contador, N. The Fungal Cell Wall: Candida, Cryptococcus, and Aspergillus Species. *Front. Microbiol.* 2019, 10, 2993. [CrossRef]

90. Plaza, V.; Silva-Moreno, E.; Castillo, L. Breakpoint: Cell Wall and Glycoproteins and their Crucial Role in the Phytopathogenic Aspergillus Species. *Front. Microbiol.* 2014, 2894–2904. [CrossRef] [PubMed]

91. Hall, R.A.; Bates, S.; Lenardon, M.D.; Maccallum, D.M.; Wagener, J.; Lowman, D.W.; Kruppa, M.D.; Williams, D.L.; Odds, F.C.; Brown, A.J.; et al. The Mnn2 mannosyltransferase family modulates mannoprotein fibril length, immune recognition and virulence of Candida albicans. *PLoS Pathog.* 2013, 9, e1003276. [CrossRef]

92. Walsh, T.J.; Giri, N. Pradimicins: A novel class of broad-spectrum antifungal compounds. *Eur. J. Clin. Microbiol. Infect. Dis.* 1997, 16, 93–97. [CrossRef]

93. Hiramoto, F.; Nomura, F.; Furumai, T.; Oki, T.; Igarashi, Y. Apoptosis-like cell death of Saccharomyces cerevisiae induced by a mannose-binding antifungal antibiotic, pradimicin. *J. Antibiot.* 2003, 56, 768–772. [CrossRef]

94. Hiramoto, F.; Nomura, F.; Furumai, T.; Igarashi, Y.; Oki, T. Pradimicin resistance of yeast is caused by a mutation of the putative N-glycosylation sites of osmosensor protein Sn1. *Biosci. Biotechnol. Biochem.* 2005, 69, 238–241. [CrossRef]

95. Yasuoka, A.; Oka, S.; Komuro, K.; Shimizu, H.; Kitada, K.; Nakamura, Y.; Shibabara, S.; Takeuchi, T.; Kondo, S.; Shimada, K.; et al. Successful treatment of Pneumocystis carinii Pneumonia in mice with benzanomicin A (ME1451). *Antimicrob. Agents Chemother.* 1995, 39, 720–724. [CrossRef]

96. Złoch, M.; Rogowska, A.; Pomastowski, P.; Railean-Plugaru, V.; Walczak-Skierska, J.; Rudnicka, J.; Buszewski, B. Use of Lactobacillus paracasei strain for zearalenone binding and metabolization. *Toxicon Off. J. Int. Soc. Toxinol.* 2020, 181, 9–18. [CrossRef] [PubMed]
97. Bejaoui, H.; Mathieu, F.; Taillandier, P.; Lebrhi, A. Ochratoxin A removal in synthetic and natural grape juices by selected oenological Saccharomyces strains. *J. Appl. Microbiol.* 2004, 97, 1038–1044. [CrossRef] [PubMed]

98. Jin, Y.; Hammer, J.; Pate, M.; Zhang, Y.; Zhu, F.; Zmuda, E.; Blazyk, J. Antimicrobial activities and structures of two linear cationic peptide families with various amphipathic beta-sheet and alpha-helical potentials. *Antimicrob. Agents Chemother.* 2005, 49, 4957–4964. [CrossRef]

99. Blazyk, J.; Wiegand, R.; Klein, J.; Hammer, J.; Epand, R.M.; Epand, R.F.; Maloy, W.L.; Kari, U.P. A novel linear amphipathic beta-sheet cationic antimicrobial peptide with enhanced selectivity for bacterial lipids. *J. Biol. Chem.* 2001, 276, 27899–27906. [CrossRef] [PubMed]

100. Martins, R.M.; Sforça, M.L.; Amino, R.; Juliano, M.A.; Oyama, S., Jr.; Juliano, L.; Pertinhez, T.A.; Spisni, A.; Schenkmman, S. Lytic activity and structural differences of amphipathic peptides derived from trialyn. *Biochemistry* 2006, 45, 1765–1774. [CrossRef]

101. Cabiaux, V.; Agerberth, B.; Johansson, J.; Homblé, F.; Goormaghtigh, E.; Ruysschaert, J.M. Secondary structure and membrane interaction of PR-39, a Pro+Arg-rich antibacterial peptide. *Eur. J. Biochem.* 1994, 224, 1019–1027. [CrossRef] [PubMed]

102. Izadpanah, A.; Gallo, R.L. Antimicrobial peptides. *Adv. Exp. Med. Biol.* 2005, 52, 381–390. [CrossRef]

103. Aoki, W.; Ueda, M. Characterization of Antimicrobial Peptides toward the Development of Novel Antibiotics. *Pharmaceuticals* 2013, 6, 1055–1081. [CrossRef]

104. Lee, J.; Lee, D.G. Antimicrobial Peptides (AMPs) with Dual Mechanisms: Membrane Disruption and Apoptosis. *Curr. Biotechnol.* 2012, 1, 72–79. [CrossRef]

105. Lee, M.T.; Chen, F.Y.; Huang, H.W. Energetics of pore formation induced by membrane active peptides. *Biochemistry* 2004, 43, 3590–3599. [CrossRef] [PubMed]

106. Lee, J.; Lee, D.G. Antimicrobial Peptides (AMPs) with Dual Mechanisms: Membrane Disruption and Apoptosis. *J. Microbiol. Biotechnol.* 2015, 25, 759–764. [CrossRef]

107. Matsuzaki, K. Membrane Permeabilization Mechanisms. *Adv. Exp. Med. Biol.* 2019, 1117, 9–16. [CrossRef] [PubMed]

108. Yamamoto, T.; Umegawa, Y.; Yamagami, M.; Suzuki, T.; Tsuchikawa, H.; Hanashima, S.; Matsumori, N.; Murata, M. The Perpendicular Orientation of Amphotericin B Methyl Ester in Hydrated Lipid Bilayers Supports the Barrel-Stave Model. *Biochemistry* 2019, 58, 2282–2291. [CrossRef] [PubMed]

109. Matsuzaki, K.; Sugishita, K.; Harada, M.; Fujii, N.; Miyajima, K. Interactions of an antimicrobial peptide, magainin 2, with outer and inner membranes of Gram-negative bacteria. *Biochim. Biophys. Acta* 2001, 1452, 119–130. [CrossRef]

110. Matsumori, N.; Tahara, K.; Yamamoto, H.; Morooka, A.; Doi, M.; Oishi, T.; Murata, M. Direct interaction between amphotericin B and ergosterol in lipid bilayers as revealed by 2H NMR spectroscopy. *J. Am. Chem. Soc.* 2009, 131, 11855–11860. [CrossRef]

111. Matsuzaki, K.; Sugishita, K.; Harada, M.; Fujii, N.; Miyajima, K. Interactions of an antimicrobial peptide, magainin 2, with outer and inner membranes of Gram-negative bacteria. *Biochim. Biophys. Acta* 2001, 1452, 119–130. [CrossRef]

112. Izadpanah, A.; Gallo, R.L. Antimicrobial peptides. *Adv. Exp. Med. Biol.* 2005, 52, 381–390. [CrossRef]

113. Aoki, W.; Ueda, M. Characterization of Antimicrobial Peptides toward the Development of Novel Antibiotics. *Pharmaceuticals* 2013, 6, 1055–1081. [CrossRef]

114. Santiano-Contador, N.; Román, E.; Sánchez-Fresneda, R.; Casas, C.; Herrero, E.; Argüelles, J.C.; Pla, J.; Cuenca-Estrella, M.; Zaragoza, O. The production of reactive oxygen species is a universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug. *Antimicrob. Agents Chemother.* 2014, 58, 6627–6638. [CrossRef]

115. Wu, G. The role of antimicrobial peptides in innate immunity: a molecular dynamics study. *J. Phys. Chem. B* 2006, 110, 16743–16753. [CrossRef] [PubMed]

116. Wang, J.; Ma, Y.; Hou, S.; Miao, Z.; Ma, Q. Interaction of amphotericin B and saturated or unsaturated phospholipid monolayers containing cholesterol or ergosterol at the air-water interface. *Biochim. Biophys. Acta* 2020, 1585, 106317. [CrossRef] [PubMed]

117. Umegawa, Y.; Nakagawa, Y.; Tahara, K.; Tsuchikawa, H.; Matsumori, N.; Oishi, T.; Murata, M. Head-to-tail interaction between amphotericin B and ergosterol occurs in hydrated phospholipid membrane. *Biochemistry* 2012, 51, 83–89. [CrossRef]

118. Santos, J.R.; Gouveia, L.F.; Taylor, E.L.; Resende-Stoianoff, M.A.; Pianetti, G.A.; César, I.C.; Santos, D.A. Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii. *Antimicrob. Agents Chemother.* 2012, 56, 2553–2558. [CrossRef]

119. Santos, J.R.; Gouveia, L.F.; Taylor, E.L.; Resende-Stoianoff, M.A.; Pianetti, G.A.; César, I.C.; Santos, D.A. Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii. *Antimicrob. Agents Chemother.* 2012, 56, 2553–2558. [CrossRef]

120. Santos, J.R.; Gouveia, L.F.; Taylor, E.L.; Resende-Stoianoff, M.A.; Pianetti, G.A.; César, I.C.; Santos, D.A. Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii. *Antimicrob. Agents Chemother.* 2012, 56, 2553–2558. [CrossRef]

121. Santos, J.R.; Gouveia, L.F.; Taylor, E.L.; Resende-Stoianoff, M.A.; Pianetti, G.A.; César, I.C.; Santos, D.A. Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii. *Antimicrob. Agents Chemother.* 2012, 56, 2553–2558. [CrossRef]

122. Santos, J.R.; Gouveia, L.F.; Taylor, E.L.; Resende-Stoianoff, M.A.; Pianetti, G.A.; César, I.C.; Santos, D.A. Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii. *Antimicrob. Agents Chemother.* 2012, 56, 2553–2558. [CrossRef]

123. Santos, J.R.; Gouveia, L.F.; Taylor, E.L.; Resende-Stoianoff, M.A.; Pianetti, G.A.; César, I.C.; Santos, D.A. Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii. *Antimicrob. Agents Chemother.* 2012, 56, 2553–2558. [CrossRef]

124. Santos, J.R.; Gouveia, L.F.; Taylor, E.L.; Resende-Stoianoff, M.A.; Pianetti, G.A.; César, I.C.; Santos, D.A. Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii. *Antimicrob. Agents Chemother.* 2012, 56, 2553–2558. [CrossRef]

125. Santos, J.R.; Gouveia, L.F.; Taylor, E.L.; Resende-Stoianoff, M.A.; Pianetti, G.A.; César, I.C.; Santos, D.A. Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii. *Antimicrob. Agents Chemother.* 2012, 56, 2553–2558. [CrossRef]

126. Santos, J.R.; Gouveia, L.F.; Taylor, E.L.; Resende-Stoianoff, M.A.; Pianetti, G.A.; César, I.C.; Santos, D.A. Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii. *Antimicrob.Agents Chemother.* 2012, 56, 2553–2558. [CrossRef]
123. Maget-Dana, R.; Peypoux, F. Iturins, a special class of pore-forming lipopeptides: Biological and physicochemical properties. *Toxicology* 1994, 87, 151–174. [CrossRef]

124. Liu, Y.; Lu, J.; Sun, J.; Zhu, X.; Zhou, L.; Lu, Z.; Lu, Y. C16-Fengycin A affect the growth of *Candida albicans* by destroying its cell wall and accumulating reactive oxygen species. *Appl. Microbiol. Biotechnol.* 2017, 101, 712–716. [CrossRef] [PubMed]

125. Sugimoto, Y.; Sakoh, H.; Yamada, K. IPC synthase as a useful target for antifungal drugs. *Curr. Drug Targets. Infect. Disord.* 2004, 4, 311–322. [CrossRef] [PubMed]

126. Nagiec, M.M.; Nagiec, E.E.; Baltisberger, J.A.; Wells, G.B.; Lester, R.L.; Dickson, R.C. Sphingolipid synthesis as a target for antifungal drugs. Complementation of the inositol phosphorylceramide synthase defect in a mutant strain of *Saccharomyces cerevisiae* by the AUR1 gene. *J. Biol. Chem.* 1997, 272, 9809–9817. [CrossRef] [PubMed]

127. Katragkou, A.; Williams, M.; Sternberg, S.; Pantazatos, D.; Rolilides, E.; Walsh, T.J. Micafungin alters the amino acid, nucleic acid and central carbon metabolism of *Candida albicans* at subinhibitory concentrations: Novel insights into mechanisms of action. *J. Antimicrob. Chemother.* 2017, 72, 712–716. [CrossRef]

128. Lee, M.R.; Raman, N.; Ortiz-Bermúdez, P.; Lynn, D.M.; Palecek, S.P. 14-Helical β-Peptides Elicit Toxicity against *C. albicans* by Forming Pores in the Cell Membrane and Subsequently Disrupting Intracellular Organelles. *Cell Chem. Biol.* 2019, 26, 289–299.e284. [CrossRef]

129. Han, J.; Wang, F.; Gao, P.; Ma, Z.; Zhao, S.; Lu, Z.; Lv, F.; Bie, X. Mechanism of action of AMP-jsa9, a LI-F-type antimicrobial peptide produced by *Paenibacillus polymyxa* Jsa-9, against *Fusarium moniliforme*. *Fungal Genet. Biol. FG B* 2017, 104, 45–55. [CrossRef]

130. Dietl, A.M.; Misslinger, M.; Aguier, M.M.; Ivashov, V.; Teis, D.; Pfister, J.; Decristoforo, C.; Hermann, M.; Sullivan, S.M.; Smith, L.R.; et al. The Siderophore Transporter Sit1 Determines Susceptibility to the Antifungal VL-2397. *Antimicrob. Agents Chemother.* 2019, 63. [CrossRef]

131. Nakamura, I.; Ohsumi, K.; Takeda, S.; Katsumata, K.; Matsumoto, S.; Akamatsu, S.; Mitori, H.; Nakai, T. ASP2397 Is a Novel Natural Compound That Exhibits Rapid and Potent Fungicidal Activity against *Aspergillus* Species through a Specific Transporter. *Antimicrob. Agents Chemother.* 2019, 63. [CrossRef]

132. Fira, D.; Dimkić, I.; Berić, T.; Lozo, J.; Stanković, S. Biological control of plant pathogens by *Bacillus* species. *J. Biotechnol.* 2018, 285, 44–55. [CrossRef] [PubMed]

133. Xu, Z.; Shao, J.; Li, B.; Yan, X.; Shen, Q.; Zhang, R. Contribution of bacillomycin D in *Bacillus amyloliquefaciens* SQR9 to antifungal activity and biofilm formation. *Appl. Environ. Microbiol.* 2013, 79, 808–815. [CrossRef] [PubMed]

134. Scott, M.G.; Hancock, R.E. Cationic antimicrobial peptides and their multifunctional role in the immune system. *Crit. Rev. Immunol.* 2000, 20, 407–431. [CrossRef] [PubMed]

135. Bonfante, P.; Genre, A. Mechanisms underlying beneficial plant-fungus interactions in mycorrhizal symbiosis. *Nat. Commun.* 2010, 1, 48. [CrossRef]

136. Ramirez-Valdespino, C.A.; Casas-Flores, S.; Olmedo-Monfil, V. Trichoderma as a Model to Study Effector-Like Molecules. *Front. Microbiol.* 2019, 10, 1030. [CrossRef] [PubMed]

137. Vinale, F.; Sivasithamparam, K. Beneficial effects of Trichoderma secondary metabolites on crops. *Phytother. Res. PTR* 2020, 34, 2835–2842. [CrossRef]

138. Marra, R.; Coppola, M.; Pironti, A.; Grasso, F.; Lombardi, N.; d’Errico, G.; Sicari, A.; Bolletti Censi, S.; Woo, S.L.; Rao, R.; et al. The Application of Trichoderma Strains or Metabolites Alters the Olive Leaf Metabolome and the Expression of Defense-Related Genes. *J. Fungi* 2020, 6, 369. [CrossRef] [PubMed]

139. Lugtenberg, B.J.; Kravchenko, L.V.; Simons, M. Tomato seed and root exudate sugars: Composition, utilization by *Pseudomonas* and central carbon metabolism of *Candida albicans* at subinhibitory concentrations: Novel insights into mechanisms of action. *Crit. Rev. Immunol.* 2000, 20, 407–431. [CrossRef] [PubMed]

140. Wang, S.; Ruan, C.; Yi, L.; Deng, L.; Yao, S.; Zeng, K. Biocontrol ability and action mechanism of *Metschnikowia citriensis* against *Fusarium moniliforme* and *Fusarium dahliae* cell death by affecting fungal signalling pathways and mediate plant defence responses involved in pathogen-associated molecular pattern-triggered immunity. *Environ. Microbiol.* 2015, 17, 1166–1188. [CrossRef] [PubMed]

141. Liu, X.; Fang, W.; Liu, L.; Yu, T.; Lou, B.; Zheng, X. Biological control of postharvest sour rot of citrus fruit. *Food Microbiol.* 2020, 87, 103375. [CrossRef]

142. Han, Q.; Wu, F.; Wang, X.; Qi, H.; Shi, L.; Ren, A.; Liu, Q.; Zhao, M.; Tang, C. The bacterial lipopeptide iturins induce Verticillium dahliae cell death by affecting fungal signalling pathways and mediate plant defence responses involved in pathogen-associated molecular pattern-triggered immunity. *Environ. Microbiol.* 2015, 17, 1166–1188. [CrossRef] [PubMed]

143. Tang, Q.; Bie, X.; Lu, Z.; Lv, F.; Tao, Y.; Qu, X. Effects of fengycin from *Bacillus subtilis* fmbJ on apoptosis and necrosis in *Rhizopus stolonifer*. *J. Microbiol. 2014*, 52, 679–680. [CrossRef] [PubMed]

144. Liu, Y.; Lu, J.; Sun, J.; Zhu, X.; Zhou, L.; Lu, Z.; Lu, Y. C16-Fengycin A affect the growth of *Candida albicans* by destroying its cell wall and accumulating reactive oxygen species. *Appl. Microbiol. Biotechnol.* 2019, 103, 8963–8975. [CrossRef]

145. Jiang, J.; Gao, L.; Bie, X.; Lu, Z.; Liu, H.; Zhang, C.; Lu, F.; Zhao, H. Identification of novel surfactin derivatives from *NRPS* modification of *Bacillus subtilis* and its antifungal activity against *Fusarium moniliforme*. *BMC Microbiol.* 2016, 16, 31. [CrossRef]

146. Tao, Y.; Bie, X.M.; Lv, F.X.; Zhao, H.Z.; Lu, Z.X. Antifungal activity and mechanism of fengycin in the presence and absence of commercial surfactin against *Rhizopus stolonifer*. *J. Microbiol.* 2011, 49, 146–150. [CrossRef] [PubMed]

147. Gupta, S.S.; Ton, V.K.; Beaudry, V.; Rulli, S.; Cunningham, K.; Rao, R. Antifungal activity of amiodarone is mediated by disruption of calcium homeostasis. *J. Biol. Chem.* 2003, 278, 28831–28839. [CrossRef]